Data Sheet | January 23, 2025
Sapient Plasma Proteomics
Get the Resource
Download NowSapient’s mass spectrometry-based plasma proteomics services are optimized to address the needs of drug developers seeking to identify drug targets and biomarkers via non-invasive liquid biopsy, without tradeoffs.
Our method provides optimal coverage of the plasma proteome while delivering high-specificity, quantitative protein measures, including PTMs and proteoforms. We leverage a fully automated pipeline including nanoflow separation coupled to Bruker timsTOF HT mass spectrometers for label-free, DIA proteomics at a throughput of 60 samples per day per instrument (60 SPD).
A unique feature of the method is our optimized single nanoparticle extraction system, specially designed to allow for capture and enrichment of low-abundance proteins and to achieve industry-leading coverage depth and breadth including capture of exosomal proteins, EVs, PTMs, and proteoforms. Our nanoparticle system uses specialized capture-and-hold chemistry that provides high quantitative accuracy across samples, for both discovery proteomics and single protein measures.
In fact, with our nanoparticle extraction system coupled to our label-free, DIA proteomics workflows, we are able to measure 5,438 total protein groups, comprising ~70,000 peptides, in 12 µl of plasma. This includes free-floating proteins as well as exosomal and membrane-bound proteins in circulation.
Sapient’s expertise also extends beyond data generation and is centered on leveraging proteomics data for key actionable insight.
Download the data sheet to see how our plasma proteomics services deliver robust, reproducible protein measures and leverage deep bioinformatics pipelines to extract biological insights from the plasma proteome for advancing drug development with:
- Coverage breadth: Measure of 5,400+ protein groups, including exosomal proteins, EVs, PTMs, and proteoforms
- Exceptional reproducibility: Low protein group technical variance (CV ~5%) and low total technical variance (CV >20%)
- Deep insight delivery: With biological pathway and drug target analyses